Epoprostenol sodium for treatment of pulmonary arterial hypertension.
about
Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension.Effect of miR-23a on anoxia-induced phenotypic transformation of smooth muscle cells of rat pulmonary arteries and regulatory mechanismCefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats.Fasudil and DETA NONOate, Loaded in a Peptide-Modified Liposomal Carrier, Slow PAH Progression upon Pulmonary Delivery.
P2860
Epoprostenol sodium for treatment of pulmonary arterial hypertension.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Epoprostenol sodium for treatment of pulmonary arterial hypertension.
@ast
Epoprostenol sodium for treatment of pulmonary arterial hypertension.
@en
type
label
Epoprostenol sodium for treatment of pulmonary arterial hypertension.
@ast
Epoprostenol sodium for treatment of pulmonary arterial hypertension.
@en
prefLabel
Epoprostenol sodium for treatment of pulmonary arterial hypertension.
@ast
Epoprostenol sodium for treatment of pulmonary arterial hypertension.
@en
P2093
P2860
P356
P1476
Epoprostenol sodium for treatment of pulmonary arterial hypertension
@en
P2093
Aiko Ogawa
Hiromi Matsubara
Hiroshi Ito
Kazufumi Nakamura
Kentaro Ejiri
Satoshi Akagi
Toshihiro Sarashina
P2860
P304
P356
10.2147/VHRM.S50368
P407
P5008
P577
2015-05-14T00:00:00Z